List of Excipients in Branded Drug MEMANTINE AND DONEPEZIL HYDROCHLORIDES

« Back to Dashboard

Generic Drugs Containing MEMANTINE AND DONEPEZIL HYDROCHLORIDES

Company	Ingredient	NDC	Excipient
ANI Pharmaceuticals Inc	memantine and donepezil hydrochlorides	62559-207	AMMONIA
ANI Pharmaceuticals Inc	memantine and donepezil hydrochlorides	62559-207	ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B
ANI Pharmaceuticals Inc	memantine and donepezil hydrochlorides	62559-207	FERROSOFERRIC OXIDE
ANI Pharmaceuticals Inc	memantine and donepezil hydrochlorides	62559-207	GELATIN
ANI Pharmaceuticals Inc	memantine and donepezil hydrochlorides	62559-207	HYDROXYPROPYL CELLULOSE
ANI Pharmaceuticals Inc	memantine and donepezil hydrochlorides	62559-207	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in MEMANTINE AND DONEPEZIL HYDROCHLORIDES?

# Of NDCs	Excipient
1	AMMONIA
1	ETHYLCELLULOSE AQUEOUS DISPERSION TYPE B
1	FERROSOFERRIC OXIDE
1	GELATIN
1	HYDROXYPROPYL CELLULOSE
1	HYPROMELLOSE 2910

Memantine and Donepezil Hydrochlorides: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 25, 2026

Memantine hydrochloride and donepezil hydrochloride are combined in Namzaric, an oral fixed-dose product for moderate-to-severe Alzheimer’s disease. The formulation pairs extended-release memantine with immediate-release donepezil in a capsule containing multiparticulate memantine pellets and an immediate-release donepezil component. The principal commercial opportunities are generic or authorized-generic substitution, alternative multiparticulate formulations, sprinkle-compatible products, lower-cost manufacturing, and differentiated adherence products.

The active ingredients are mature and broadly genericized as individual products. The commercial barrier is therefore concentrated in the fixed-dose combination, release architecture, bioequivalence package, capsule manufacture, and any surviving formulation or method-of-use patents.

What is Namzaric and how is the combination formulated?

Namzaric is an FDA-approved fixed-dose combination of memantine hydrochloride extended release and donepezil hydrochloride immediate release. FDA approved the product in 2014 under NDA 206439 for patients with moderate-to-severe Alzheimer’s disease who are stabilized on both components.[1]

Product characteristic	Namzaric profile
Active ingredients	Memantine hydrochloride and donepezil hydrochloride
Memantine component	Extended release
Donepezil component	Immediate release
Dosage form	Oral capsule
Memantine strengths	7 mg, 14 mg, 21 mg, 28 mg
Donepezil strength	10 mg in marketed fixed-dose presentations
Indication	Moderate-to-severe Alzheimer’s disease
Regulatory pathway	New drug application
Reference product	Namzaric
Sponsor history	Forest Laboratories, Actavis and subsequent Allergan/AbbVie ownership history
Key technical feature	Combination of different release profiles in one capsule

The product is intended for patients already receiving memantine and donepezil. The dosage is titrated through memantine extended-release strengths while the donepezil dose remains 10 mg in the marketed combination.[1]

The dosage form creates a technical distinction from conventional immediate-release fixed-dose tablets. Memantine must provide controlled exposure over approximately 24 hours, while donepezil must release promptly. A single matrix tablet could theoretically provide both profiles, but a multiparticulate capsule more readily separates the two release systems and permits independent optimization.

What excipient strategy supports memantine and donepezil hydrochlorides?

The most commercially relevant excipient strategy is a dual-release multiparticulate platform. Memantine hydrochloride is incorporated into extended-release pellets or beads, while donepezil hydrochloride is delivered through an immediate-release component. The capsule shell provides the final unit-dose presentation.

Memantine extended-release pellets

A typical memantine pellet system can use:

• A drug-loaded inert core or directly formed pellet
• A hydrophilic binder such as povidone or hydroxypropyl cellulose
• An extended-release polymer such as ethylcellulose
• A pore former or hydrophilic polymer to control water penetration
• Talc or another anti-tacking agent
• A plasticizer, where needed, to improve film integrity
• A protective overcoat to reduce moisture transfer and mechanical damage

The release rate must remain stable across the 7 mg, 14 mg, 21 mg and 28 mg strengths. A manufacturer can scale dose by increasing pellet mass, changing pellet count, or adjusting drug loading. Keeping the same pellet architecture across strengths reduces manufacturing complexity and supports a common bioequivalence strategy.

Ethylcellulose-based coatings are commercially attractive because they are established for sustained-release multiparticulates and can be adjusted through coating weight, porosity and plasticizer level. Hydrophilic polymers can be used to create a diffusion-controlled layer or to accelerate hydration. The final selection depends on dissolution targets, coating equipment, drug loading and the desired sensitivity to food and gastrointestinal conditions.

Donepezil immediate-release component

Donepezil hydrochloride is suitable for immediate-release delivery because the combination requires prompt exposure from the donepezil portion. The immediate-release component can be a small tablet, granule or drug-loaded pellet placed inside the same capsule as the memantine multiparticulates.

Relevant excipient functions include:

• A water-soluble filler to support rapid dissolution
• A binder to maintain mechanical integrity
• A disintegrant to promote rapid breakup
• A glidant to improve powder flow
• A lubricant selected to avoid slowing dissolution
• A film coat for identification and handling, if required

The formulation should avoid excessive hydrophobic lubrication or dense coatings that delay donepezil release. A small immediate-release tablet may simplify content uniformity and dose control. A pellet-based approach can provide greater flexibility for sprinkle products and may reduce segregation risk when combined with memantine pellets.

Capsule shell and product robustness

The capsule shell must tolerate the moisture and mechanical requirements of a multiparticulate product. Gelatin is conventional, while hypromellose capsules can provide a vegetarian alternative and may offer different moisture behavior. Shell selection affects:

• Moisture migration
• Brittleness during packaging
• Compatibility with desiccants
• Dissolution after storage
• Printing and product identification
• Patient acceptance

A major formulation objective is preventing pellet abrasion during encapsulation, shipping and patient handling. Broken extended-release coatings can cause dose-dumping or accelerate memantine release. The capsule fill process therefore becomes part of the product’s critical quality profile.

What excipients are associated with the marketed product?

FDA labeling identifies Namzaric as a capsule containing memantine hydrochloride extended-release and donepezil hydrochloride immediate-release components. The inactive-ingredient profile includes conventional pellet and capsule excipients such as sugar spheres, povidone, ethylcellulose, talc, hypromellose, polyethylene glycol and capsule-shell materials, with colorants varying by strength.[1]

The exact excipient composition should be taken from the current FDA prescribing information and the approved product labeling. A generic manufacturer does not need to copy every excipient. It must establish pharmaceutical equivalence, bioequivalence and acceptable quality under the applicable abbreviated new drug application requirements.

The practical target is functional equivalence:

Formulation function	Commercial objective
Extended-release membrane	Match memantine dissolution and exposure
Immediate-release component	Match early donepezil release
Binder system	Maintain pellet and tablet integrity
Anti-tacking system	Support efficient coating
Capsule shell	Protect product and control moisture
Overcoat	Limit abrasion and improve stability
Disintegrant system	Avoid delayed donepezil release
Lubricant system	Preserve flow without compromising dissolution

What formulation patents protect memantine and donepezil hydrochlorides?

The highest-value intellectual property is likely to relate to the combination architecture rather than the individual active ingredients. Memantine hydrochloride and donepezil hydrochloride have long-established use in Alzheimer’s disease, and both active ingredients have generic products. The defensible patent categories include:

1. Fixed-dose combinations of memantine and donepezil.
2. Memantine extended-release combined with donepezil immediate-release.
3. Multiparticulate capsules containing separate release populations.
4. Specific dose combinations and titration schedules.
5. Methods of treating moderate-to-severe Alzheimer’s disease with the combination.
6. Manufacturing methods for coating, blending and encapsulation.
7. Stability improvements involving moisture barriers or protective coatings.

The FDA Orange Book remains the primary source for listed patents and regulatory exclusivity associated with Namzaric. Patent status can differ by claim scope, terminal disclaimers, patent-term adjustment, pediatric extensions and litigation outcome. A commercial decision should therefore distinguish between:

• Patents listed in the Orange Book
• Patents that remain legally unexpired
• Claims that cover the proposed product
• Claims that can support an infringement action
• Patents that have been invalidated, disclaimed or narrowed

The individual active ingredients do not create a meaningful composition-of-matter barrier for a new fixed-dose product. A generic sponsor’s principal risk is a formulation or method-of-use patent that reads on its specific capsule architecture or labeling.

When does Namzaric lose exclusivity?

Namzaric’s regulatory exclusivity began with its FDA approval in 2014. The product’s new-drug exclusivity period has expired, allowing ANDA-based generic competition subject to applicable patent certifications and any remaining enforceable patent rights.[1,2]

Regulatory exclusivity and patent protection are separate:

Protection	Commercial relevance
New-drug exclusivity	Restricts certain FDA submissions for a defined period
Orange Book patents	Can delay approval or launch after Paragraph IV litigation
Formulation patents	May cover release systems or dosage forms
Method-of-use patents	May require carve-outs or litigation
Manufacturing patents	Can affect process selection but may be harder to enforce against a finished product
Trademarks	May restrict branding but do not prevent generic approval

A precise launch date requires review of the current Orange Book, patent certifications, litigation records and any settlement agreements. The expiration of regulatory exclusivity alone does not establish freedom to launch.

What is the Orange Book status of Namzaric?

Namzaric is listed in FDA’s Orange Book through its approved NDA. The Orange Book identifies approved products, therapeutic equivalence information and patent or exclusivity data submitted for listing.[2]

A generic applicant seeking approval for memantine hydrochloride and donepezil hydrochloride capsules would normally evaluate an ANDA pathway. The applicant may need to submit:

• Paragraph I certification if no relevant patent is listed
• Paragraph II certification if the listed patent has expired
• Paragraph III certification if the applicant will wait for expiration
• Paragraph IV certification if the applicant asserts that a listed patent is invalid, unenforceable or not infringed

The 30-month stay risk under a Paragraph IV strategy depends on whether the reference sponsor or patent owner files suit within the statutory period. A Paragraph IV filing may create an earlier approval opportunity but increases legal cost and launch uncertainty.

Which companies are challenging the Namzaric franchise?

The likely competitive field includes manufacturers with established Alzheimer’s generic portfolios, controlled-release multiparticulate capabilities and experience with complex ANDAs. Potential competitors include large generic companies, specialty pharmaceutical manufacturers and contract development and manufacturing organizations operating through development partnerships.

Competition is not limited to an identical fixed-dose capsule. It also includes:

• Generic memantine extended-release capsules
• Generic donepezil tablets
• Separate-pill regimens
• Authorized-generic supply
• Other fixed-dose Alzheimer’s combinations
• Alternative oral dosage forms

A challenger with a simple immediate-release tablet may face less technical development risk but may not match Namzaric’s release profile. A multiparticulate challenger has a stronger substitution position but must control coating variability, capsule fill weight and dissolution across all strengths.

What generic entry risks exist?

The principal generic entry risks are technical, legal and commercial.

Technical risks

The highest technical risks include:

• Failure to match memantine extended-release dissolution
• Early release of memantine caused by coating defects
• Delayed release of donepezil
• Food-effect differences
• Capsule-to-capsule pellet segregation
• Dose nonuniformity across multiple strengths
• Stability failures caused by moisture ingress
• In-vitro and in-vivo correlation problems

A formulation that matches the reference product at a single pH may diverge under the full dissolution method. The development program should evaluate multiple pH conditions, agitation rates, buffer capacity and alcohol exposure where relevant.

Legal risks

A Paragraph IV applicant may face:

• Patent infringement litigation
• A 30-month stay of approval
• A settlement restricting launch timing
• A covenant not to sue limited to specific formulations
• Risks from method-of-use claims
• Claims based on the manufacturing process or pellet structure

A product designed around a different polymer system may reduce literal infringement risk but does not eliminate the possibility of a doctrine-of-equivalents claim.

Commercial risks

Namzaric patients are generally older and may have caregivers managing medication. Switching friction can be high if the generic has different capsule appearance, administration instructions or sprinkle behavior. Payers may favor a lower-cost generic, but prescribers and caregivers may continue using the branded product when the patient is stable.

What commercial opportunities exist for excipient suppliers and drug developers?

Generic fixed-dose capsules

The largest opportunity is an AB-rated generic equivalent with the same active strengths and release profiles. The product requires a robust multiparticulate platform but benefits from established active ingredients and a defined reference product.

Sprinkle-compatible products

A capsule that can be opened and sprinkled on applesauce or another soft food can address swallowing difficulty, a common issue in older Alzheimer’s patients. The product must demonstrate that opening the capsule does not damage the extended-release coating or alter dose delivery.

Sprinkle compatibility creates opportunities for:

• Caregiver-focused packaging
• Unit-dose administration
• Long-term-care pharmacy supply
• Home-health medication programs
• Specialty adherence services

The label and comparative performance must support the administration method. A manufacturer should not assume that a capsule can be opened safely merely because its contents are multiparticulate.

Alternative capsule technologies

Hypromellose capsules, moisture-protective shells and low-friction capsule systems can differentiate a product without changing the active ingredients. Such changes may improve stability, reduce animal-derived materials or support regional market preferences.

Lower-cost manufacturing

Manufacturers can seek cost advantages through:

• Higher drug loading
• Fewer coating steps
• Continuous fluid-bed coating
• Common pellet platforms across strengths
• Standardized capsule-fill equipment
• Reduced overcoat weight
• Improved yield and lower pellet attrition

The lowest-cost process is not necessarily the best commercial process. A small reduction in coating material may increase dissolution variability and batch failure risk.

Geographic expansion

The fixed-dose combination has potential in markets with growing Alzheimer’s diagnosis and caregiver-managed medication use. Regional opportunities depend on:

• Patent status
• Local regulatory recognition of the reference product
• Reimbursement for combination therapy
• Availability of memantine and donepezil as separate products
• Local requirements for clinical or bioequivalence data
• Import controls and manufacturing localization

The United States is attractive because of the ANDA pathway and established Orange Book framework. Europe and other regulated markets may require separate pharmaceutical equivalence and bioequivalence strategies, even where the active ingredients are well established.

How strong is the patent estate for the combination?

The estate is stronger against a direct copy of the branded release architecture than against all memantine-donepezil combinations. The individual molecules are old, but a claimed combination of extended-release memantine and immediate-release donepezil may remain commercially relevant if a listed patent is unexpired and its claims cover the proposed product.

Patent strength should be assessed across five dimensions:

Factor	Assessment
Active-ingredient patents	Weak or largely exhausted because both ingredients are mature
Fixed-dose combination claims	Potentially material
Release-profile claims	Material for products using the same architecture
Method-of-use claims	Relevant to labeling and indication strategy
Manufacturing claims	More design-around potential, but still relevant in litigation

The strongest design-around strategy generally uses a different release-control mechanism, different pellet construction or a different manufacturing sequence while preserving bioequivalence. That strategy can increase development cost and regulatory risk.

What patent litigation and settlement issues affect launch timing?

A Paragraph IV challenge can trigger litigation before approval. The key commercial dates are the filing date, notice date, lawsuit date, 30-month stay, patent expiration dates and any agreed launch date.

Settlement agreements may provide:

• An agreed generic launch date
• A license before patent expiration
• Authorized-generic supply
• Restrictions on formulations or strengths
• No-challenge provisions
• Acceleration provisions if a patent is invalidated

The FTC and FDA may scrutinize pharmaceutical patent settlements for anticompetitive terms. A settlement that permits an earlier launch can still restrict manufacturing, distribution or product configuration.

How does the combination compare with separate memantine and donepezil products?

Attribute	Fixed-dose combination	Separate products
Pill burden	Lower	Higher
Dose flexibility	Limited by marketed combinations	Greater
Adherence	Potentially improved	More regimen complexity
Titration	Memantine-focused	Each product can be adjusted
Manufacturing	Complex dual-release dosage form	Simpler individual products
Generic substitution	Combination-specific	Mature and competitive
Caregiver administration	More convenient	Requires coordination
Patent exposure	Concentrated in combination formulation	Generally lower for mature products

The fixed-dose combination has a commercial rationale where adherence and caregiver simplicity outweigh the loss of dose flexibility. Its value is weaker when patients require individualized donepezil or memantine titration.

Key Takeaways

• Namzaric combines memantine hydrochloride extended release with donepezil hydrochloride immediate release in one capsule.
• The central formulation opportunity is a dual-release multiparticulate system with independently controlled memantine and donepezil components.
• The most important excipient functions are membrane-controlled release, pellet integrity, rapid donepezil disintegration, moisture protection and capsule robustness.
• Regulatory exclusivity has expired, but remaining Orange Book patents and litigation can affect generic launch timing.
• Generic development is technically more complex than development of either active ingredient alone.
• Sprinkle-compatible capsules, hypromellose shells, caregiver packaging and lower-cost coating processes are the clearest product-development opportunities.
• Patent risk is concentrated in fixed-dose combination, release-profile, method-of-use and manufacturing claims rather than in the active ingredients.
• A Paragraph IV strategy can create an earlier launch opportunity but introduces litigation, stay and settlement risk.

FAQs

Can memantine and donepezil hydrochlorides be combined in an immediate-release tablet?

Yes, but an immediate-release tablet would not be equivalent to Namzaric unless it produced the required memantine extended-release exposure. It would likely require a different regulatory and bioequivalence strategy.

Which excipient controls the extended release of memantine?

An extended-release polymer, commonly an ethylcellulose-based coating or another diffusion-control system, is the principal release-controlling element. Pore formers, plasticizers and overcoats also influence the final dissolution profile.

Is a sprinkle formulation automatically therapeutically equivalent?

No. Opening a capsule can alter pellet handling, dose recovery, moisture exposure or release performance. A sponsor must support the administration method with product-performance data and appropriate labeling.

Can a generic manufacturer use different excipients from Namzaric?

Yes, subject to applicable FDA requirements. The generic must demonstrate pharmaceutical equivalence, bioequivalence, quality, stability and acceptable safety of the inactive ingredients.

Is a fixed-dose memantine-donepezil product protected by the patents on either active ingredient?

Generally, the commercial patent risk is more likely to arise from combination, formulation, release-profile or method-of-use claims than from new composition-of-matter patents covering memantine or donepezil individually.

References

1. U.S. Food and Drug Administration. (2023). Namzaric (memantine hydrochloride and donepezil hydrochloride) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2014). Namzaric approval letter and NDA 206439 regulatory history.
4. U.S. Food and Drug Administration. (2023). Generic drugs: Abbreviated new drug application requirements and therapeutic equivalence.